KROS
NASDAQ
$10.61
Keros Therapeutics Inc (KROS)
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $21.83 (+105.75%)
Market Cap
$218M
P/B Ratio
0.73
Free Cash Flow Yield
-26.76%
Beta (5Y)
0.59
Price Chart
Valuation
Market Cap$218M
Forward P/E48.78
P/S6.58
P/B0.73
Profitability
Total Revenue (TTM)$33M
Gross Profit (TTM)-$61M
EBITDA-$109M
Profit Margin-256.6%
Operating Margin-7051%
EPS-$3.34
Financial Health
Free Cash Flow Yield-26.76%
Growth & Risk
EPS 5Y CAGR+7.98%
FCF 5Y CAGR+8.02%
Beta (5Y)0.59
Sharpe Ratio-0.45